Labcorp announced strong fourth quarter and full year 2025 results, with revenue growing over 7% and double-digit adjusted EPS growth, driven by strength in Diagnostics and Central Laboratory businesses. The company also provided optimistic guidance for 2026, anticipating continued strong performance.
Q4 2025 revenue increased to $3.52 billion from $3.33 billion in Q4 2024, a 5.6% increase.
Diluted EPS for Q4 2025 rose to $1.98 from $1.70 in Q4 2024, reflecting improved profitability.
Adjusted EPS for Q4 2025 reached $4.07, up from $3.45 in Q4 2024, indicating strong operational performance.
Free Cash Flow for Q4 2025 was $490.3 million, compared to $665.1 million in Q4 2024, primarily due to working capital timing.
Labcorp provided 2026 guidance anticipating continued growth across all segments, with enterprise revenue projected to increase by 4.7% to 6.0%, adjusted EPS by 8.9% at midpoint, and free cash flow by 7.8% at midpoint.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance